Condition: Schizophrenia and Related Disorders · Early Treatment-Resistance · Sponsor: Dr. Inge Winter
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros. The impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue scholing, to a low quality of life, impaired cognitive functioning, suicidal ideation and an increase morbidity rate, next to the large burden for carers 1. When diagnosed with schizophrenia or related disorder, patients are commonly prescribed antipsychotics. One-third of the schizophrenia patients are regarded treatment-resistant (TR), meaning that at least two antipsychotic trials have failed. Typically, clozapine is prescribed for TR patients, which is effective for approximately 40% of patients. Clozapine is among the most effective treatments, with the lowest all-cause mortality. Although it is among the most effective antipsychotics, it is generally not used earlier in the illness course due to a small risk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine are intensely monitored. However, this small risk outweighs the burden of not receiving an effective treatment. Since clozapine is among the most effective treatments, this leads to the research question whether earlier initiation of third-line treatment ('early intensified' pharmacological treatment; EIPT) would be more beneficial than the current second-line treatment…
This description comes directly from the study's public registry record.
Inge Winter, Dr. · +31875553227 · i.winter@umcutrecht.nl
Cynthia Okhuijsen-Pfeifer, Dr. · +31875553227 · c.pfeifer@umcutrecht.nl
Always discuss trial participation with your own doctor first.
| Medical University Innsbruck | Innsbruck, Austria | Recruiting |
| Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg | Augsburg, Germany | Not Yet Recruiting |
| Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld | Bielefeld, Germany | Recruiting |
| LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft | Dortmund, Germany | Recruiting |
| University Hospital Frankfurt am Main - Goethe University | Frankfurt am Main, Germany | Recruiting |
| Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz | Mainz, Germany | Recruiting |
| Westfälische Wilhelms-Universität Münster | Münster, Germany | Recruiting |
| Universita degli Studi di Brescia | Brescia, Italy | Recruiting |
| University of Cagliari | Cagliari, Italy | Recruiting |
| Università degli studi della Campania Luigi Vanvitelli | Naples, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino" | Turin, Italy | Recruiting |
| Fundació Clínic per a la Recerca Biomèdica | Barcelona, Spain | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05958875